Mittie Doyle, chief medical officer of Avalo Therapeutics Inc., disposed of 1,000 common shares on August 17 under a pre-established Rule 10b5-1 trading plan adopted on November 13, 2025. The shares were sold at $20.00 each for a total transaction value of $20,000, according to a regulatory filing.
The transaction occurred as part of a scheduled plan, with Doyle exercising 1,000 stock options at $12.65 per share for a total cost of $12,650. Following the sale and exercise, Doyle holds 51,776 direct common shares and 123,750 derivative securities in the form of stock options.
Avalo Therapeutics' shares have gained 108% over the past 12 months, closing at $19.74 on August 25. The company's inclusion in the Russell 2000 and Russell 3000 indices was announced earlier this year, with the Russell 3000 tracking the 3,000 largest U.S. public companies and the Russell 2000 serving as a small-cap benchmark.
Analyst coverage remains constructive. Leerink initiated coverage with an Outperform rating and a $38 price target, while Cantor Fitzgerald maintained an Overweight rating, citing Phase 2 data for the company's experimental drug abdakibart in hidradenitis suppurativa. InvestingPro analysis suggests the stock appears overvalued relative to its fair value, despite the optimistic targets.
Ron Philip, appointed to the board in July 2025, will serve on the Compensation Committee and the Science, Development, and Commercial Advisory Committee, bringing over 30 years of biopharmaceutical experience.
